Druggable orthosteric and allosteric hot spots to target protein-protein interactions

Current Pharmaceutical Design

Volumn 20, Issue 8, 2014, Pages 1293-1301

  Ma, Buyong ^a   Nussinov, Ruth ^a,b  

^a FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Allosteric drugs; Allostery; Amyloid; Drug discovery; Protein binding site; Protein pockets; Protein protein interfaces

Indexed keywords

ABC TRANSPORTER; CHEMOKINE RECEPTOR CXCR1; DRUG BINDING PROTEIN; EPHRIN RECEPTOR; EPHRIN RECEPTOR A2; EPHRIN RECEPTOR B4; GLYCOPROTEIN GP 160; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 8; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE C; RAS PROTEIN; TRANSCRIPTION FACTOR 7 LIKE 1; LIGAND; PEPTIDE; PROTEIN; PROTEIN BINDING;

ALLOSTERIC HOT SPOT; ARTICLE; DRUG BINDING SITE; DRUG DESIGN; DRUG STRUCTURE; HUMAN; NONHUMAN; ORTHOSTERIC HOT SPOT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; SIGNAL TRANSDUCTION; ALLOSTERISM; BINDING SITE; BIOLOGY; CHEMICAL STRUCTURE; CHEMISTRY;

ALLOSTERIC REGULATION; ALLOSTERIC SITE; COMPUTATIONAL BIOLOGY; DRUG DESIGN; HUMANS; LIGANDS; MODELS, MOLECULAR; PEPTIDES; PROTEIN BINDING; PROTEINS; RAS PROTEINS; RECEPTORS, EPH FAMILY;

EID: 84902833898     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990073     Document Type: Article

References (118)

1. Kennedy D, Norman C. What don't we know? Science 2005; 309: 75.
2. Keskin O, Gursoy A, Ma B, Nussinov R. Principles of proteinprotein interactions: what are the preferred ways for proteins to interact? Chem Rev 2008; 108: 1225-44.
3. Keskin O, Ma B, Rogale K, Gunasekaran K, Nussinov R. Proteinprotein interactions: organization, cooperativity and mapping in a bottom-up Systems Biology approach. Phys Biol 2005; 2: S24-35.
4. Ma B, Pan Y, Gunasekaran K, et al. The contribution of the Trp/Met/Phe residues to physical interactions of p53 with cellular proteins. Phys Biol 2005; 2: S56-66.
5. Vousden KH, Prives C. Blinded by the Light: The Growing Complexity of p53. Cell 2009; 137: 413-31.
6. Belyi VA, Levine AJ. One billion years of p53/p63/p73 evolution. Proc Natl Acad Sci USA 2009; 106: 17609-10.
7. Cox AD, Der CJ. Ras history: The saga continues. Small GTPases 2010; 1: 2-27.
8. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature 2009; 458: 719-24.
9. Prior IA, Lewis PD, Mattos C. A comprehensive survey of Ras mutations in cancer. Cancer Res 2012; 72: 2457-67.
10. Ryan DP, Matthews JM. Protein-protein interactions in human disease. Curr Opin Struct Biol 2005; 15: 441-6.
11. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998; 393: 648-59.
12. Sillerud LO, Larson RS. Design and structure of peptide and peptidomimetic antagonists of protein-protein interaction. Curr Protein Pept Sci 2005; 6: 151-69.
13. Pommier Y, Cherfils J. Interfacial inhibition of macromolecular interactions: nature's paradigm for drug discovery. Trends Pharmacol Sci 2005; 26: 138-45.
14. Zhao L, Chmielewski J. Inhibiting protein-protein interactions using designed molecules. Curr Opin Struct Biol 2005; 15: 31-4.
15. Loregian A, Palu G. Disruption of protein-protein interactions: towards new targets for chemotherapy. J Cell Physiol 2005; 204: 750-62.
16. Arkin MR, Wells JA. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat Rev Drug Discov 2004; 3: 301-17.
17. Fry DC, Vassilev LT. Targeting protein-protein interactions for cancer therapy. J Mol Med 2005; 83: 955-63.
18. Yin H, Hamilton AD. Strategies for targeting protein-protein interactions with synthetic agents. Angew Chem Int Ed Engl 2005; 44: 4130-63.
19. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP. Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer 2009; 9: 862-73.
20. Sperandio O, Reynes CH, Camproux AC, Villoutreix BO. Rationalizing the chemical space of protein-protein interaction inhibitors. Drug Discov Today 2010; 15: 220-9.
21. Lise S, Archambeau C, Pontil M, Jones DT. Prediction of hot spot residues at protein-protein interfaces by combining machine learning and energy-based methods. BMC Bioinformatics 2009; 10: 365.
22. Janin J, Wodak SJ. Protein modules and protein-protein interaction. Introduction. Adv Protein Chem 2002; 61: 1-8.
23. Reichmann D, Rahat O, Albeck S, Meged R, Dym O, Schreiber G. The modular architecture of protein-protein binding interfaces. Proc Natl Acad Sci USA 2005; 102: 57-62.
24. Keskin O, Ma B, Nussinov R. Hot regions in protein--protein interactions: the organization and contribution of structurally conserved hot spot residues. J Mol Biol 2005; 345: 1281-94.
25. Bogan AA, Thorn KS. Anatomy of hot spots in protein interfaces. J Mol Biol 1998; 280: 1-9.
26. Ward JM, Gorenstein NM, Tian J, Martin SF, Post CB. Constraining binding hot spots: NMR and molecular dynamics simulations provide a structural explanation for enthalpy-entropy compensation in SH2-ligand binding. J Am Chem Soc 2010; 132: 11058-70.
27. Ma B, Elkayam T, Wolfson H, Nussinov R. Protein-protein interactions: structurally conserved residues distinguish between binding sites and exposed protein surfaces. Proc Natl Acad Sci USA 2003; 100: 5772-7.
28. Ma B, Wolfson HJ, Nussinov R. Protein functional epitopes: hot spots, dynamics and combinatorial libraries. Curr Opin Struct Biol 2001; 11: 364-9.
29. Thanos CD, DeLano WL, Wells JA. Hot-spot mimicry of a cytokine receptor by a small molecule. Proc Natl Acad Sci USA 2006; 103: 15422-7.
30. Arkin MR, Whitty A. The road less traveled: modulating signal transduction enzymes by inhibiting their protein-protein interactions. Curr Opin Chem Biol 2009; 13: 284-90.
31. Kossiakoff AA, Koide S. Understanding mechanisms governing protein-protein interactions from synthetic binding interfaces. Curr Opin Struct Biol 2008; 18: 499-506.
32. Tuncbag N, Gursoy A, Keskin O. Identification of computational hot spots in protein interfaces: combining solvent accessibility and inter-residue potentials improves the accuracy. Bioinformatics 2009; 25: 1513-20.
33. Moreira IS, Fernandes PA, Ramos MJ. Hot spots--a review of the protein-protein interface determinant amino-acid residues. Proteins 2007; 68: 803-12.
34. Carbonell P, Nussinov R, del Sol A. Energetic determinants of protein binding specificity: insights into protein interaction networks. Proteomics 2009; 9: 1744-53.
35. Reichmann D, Cohen M, Abramovich R, et al. Binding hot spots in the TEM1-BLIP interface in light of its modular architecture. J Mol Biol 2007; 365: 663-79.
36. Ozbabacan SE, Gursoy A, Keskin O, Nussinov R. Conformational ensembles, signal transduction and residue hot spots: application to drug discovery. Curr Opin Drug Discov Devel 2010; 13: 527-37.
37. Tuncbag N, Kar G, Gursoy A, Keskin O, Nussinov R. Towards inferring time dimensionality in protein-protein interaction networks by integrating structures: the p53 example. Mol Biosyst 2009; 5: 1770-8.
38. Cho KI, Kim D, Lee D. A feature-based approach to modeling protein-protein interaction hot spots. Nucleic Acids Res 2009; 37: 2672-87.
39. Meliciani I, Klenin K, Strunk T, Schmitz K, Wenzel W. Probing hot spots on protein-protein interfaces with all-atom free-energy simulation. J Chem Phys 2009; 131: 034114.
40. Chen R, Zhang Z, Wu D, Zhang P, Zhang X, Wang Y, Shi Y. Prediction of protein interaction hot spots using rough set-based multiple criteria linear programming. J Theor Biol 2010.
41. Tuncbag N, Keskin O, Gursoy A. HotPoint: hot spot prediction server for protein interfaces. Nucleic Acids Res 2010; 38 Suppl: W402-6.
42. Segura Mora J, Assi SA, Fernandez-Fuentes N. Presaging critical residues in protein interfaces-web server (PCRPi-W): a web server to chart hot spots in protein interfaces. PLoS One 2010; 5: e12352.
43. Darnell SJ, LeGault L, Mitchell JC. KFC Server: interactive forecasting of protein interaction hot spots. Nucleic Acids Res 2008; 36: W265-9.
44. Li X, Keskin O, Ma B, Nussinov R, Liang J. Protein-protein interactions: hot spots and structurally conserved residues often locate in complemented pockets that pre-organized in the unbound states: implications for docking. J Mol Biol 2004; 344: 781-95.
45. Fuller JC, Burgoyne NJ, Jackson RM. Predicting druggable binding sites at the protein-protein interface. Drug Discov Today 2009; 14: 155-61.
46. Rajamani D, Thiel S, Vajda S, Camacho CJ. Anchor residues in protein-protein interactions. Proc Natl Acad Sci USA 2004; 101: 11287-92.
47. Meireles LM, Domling AS, Camacho CJ. ANCHOR: a web server and database for analysis of protein-protein interaction binding pockets for drug discovery. Nucleic Acids Res 2010; 38 Suppl: W407-11.
48. Trosset JY, Dalvit C, Knapp S, et al. Inhibition of protein-protein interactions: the discovery of druglike beta-catenin inhibitors by combining virtual and biophysical screening. Proteins 2006; 64: 60-7.
49. Seco J, Luque FJ, Barril X. Binding site detection and druggability index from first principles. J Med Chem 2009; 52: 2363-71.
50. Sugaya N, Ikeda K. Assessing the druggability of protein-protein interactions by a supervised machine-learning method. BMC Bioinformatics 2009; 10: 263.
51. Sperandio O, Miteva MA, Segers K, Nicolaes GA, Villoutreix BO. Screening Outside the Catalytic Site: Inhibition of Macromolecular Inter-actions Through Structure-Based Virtual Ligand Screening Experiments. Open Biochem J 2008; 2: 29-37.
52. Surade S, Blundell TL. Structural biology and drug discovery of difficult targets: the limits of ligandability. Chem Biol 2012; 19: 42-50.
53. Yuan P, Liang K, Ma B, Zheng N, Nussinov R, Huang J. Multipletargeting and conformational selection in the estrogen receptor: computation and experiment. Chem Biol Drug Des 2011; 78: 137-49.
54. Kozakov D, Hall DR, Chuang GY, et al. Structural conservation of druggable hot spots in protein-protein interfaces. Proc Natl Acad Sci USA 2011; 108: 13528-33.
55. Hirai H, Maru Y, Hagiwara K, Nishida J, Takaku F. A novel putative tyrosine kinase receptor encoded by the eph gene. Science 1987; 238: 1717-20.
56. Salaita K, Nair PM, Petit RS, et al. Restriction of receptor movement alters cellular response: physical force sensing by EphA2. Science 2010; 327: 1380-5.
57. Simon AM, de Maturana RL, Ricobaraza A, et al. Early changes in hippocampal Eph receptors precede the onset of memory decline in mouse models of Alzheimer's disease. J Alzheimers Dis 2009; 17: 773-86.
58. Genander M, Frisen J. Ephrins and Eph receptors in stem cells and cancer. Curr Opin Cell Biol 2010; 22: 611-6.
59. Chen J, Zhuang G, Frieden L, Debinski W. Eph receptors and Ephrins in cancer: common themes and controversies. Cancer Res 2008; 68: 10031-3.
60. Surawska H, Ma PC, Salgia R. The role of ephrins and Eph receptors in cancer. Cytokine Growth Factor Rev 2004; 15: 419-33.
61. Xi HQ, Wu XS, Wei B, Chen L. Eph receptors and ephrins as targets for cancer therapy. J Cell Mol Med 2012; 16: 2894-909.
62. Pasquale EB. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer 2010; 10: 165-80.
63. Garber K. Of Ephs and ephrins: companies target guidance molecules in cancer. J Natl Cancer Inst 2010; 102: 1692-4.
64. Noberini R, Lamberto I, Pasquale EB. Targeting Eph receptors with peptides and small molecules: progress and challenges. Semin Cell Dev Biol 2012; 23: 51-7.
65. Murai KK, Nguyen LN, Koolpe M, McLennan R, Krull CE, Pasquale EB. Targeting the EphA4 receptor in the nervous system with biologically active peptides. Mol Cell Neurosci 2003; 24: 1000-11.
66. Lamberto I, Qin H, Noberini R, et al. Distinctive binding of three antagonistic peptides to the ephrin-binding pocket of the EphA4 receptor. Biochem J 2012; 445: 47-56.
67. Koolpe M, Dail M, Pasquale EB. An ephrin mimetic peptide that selectively targets the EphA2 receptor. J Biol Chem 2002; 277: 46974-9.
68. Mitra S, Duggineni S, Koolpe M, Zhu X, Huang Z, Pasquale EB. Structure-activity relationship analysis of peptides targeting the EphA2 receptor. Biochemistry 2010; 49: 6687-95.
69. Duggineni S, Mitra S, Noberini R, et al. Design, synthesis and characterization of novel small molecular inhibitors of ephrin-B2 binding to EphB4. Biochem Pharmacol 2013; 85: 507-13.
70. Chrencik JE, Brooun A, Recht MI, et al. Three-dimensional structure of the EphB2 receptor in complex with an antagonistic peptide reveals a novel mode of inhibition. J Biol Chem 2007; 282: 36505-13.
71. Peng L, Oganesyan V, Damschroder MM, Wu H, Dall'Acqua WF. Structural and functional characterization of an agonistic antihuman EphA2 monoclonal antibody. J Mol Biol 2011; 413: 390-405.
72. Ansuini H, Meola A, Gunes Z, et al. Anti-EphA2 Antibodies with Distinct In vitro Properties Have Equal In vivo Efficacy in Pancreatic Cancer. J Oncol 2009; 2009: 951917.
73. Abengozar MA, de Frutos S, Ferreiro S, et al. Blocking ephrinB2 with highly specific antibodies inhibits angiogenesis, lymphangiogenesis, and tumor growth. Blood 2012; 119: 4565-76.
74. Schreiber G, Keating AE. Protein binding specificity versus promiscuity. Curr Opin Struct Biol 2011; 21: 50-61.
75. Easty DJ, Gray SG, O'Byrne KJ, O'Donnell D, Bennett DC. Receptor tyrosine kinases and their activation in melanoma. Pigment Cell Melanoma Res 2011; 24: 446-61.
76. Nakada M, Niska JA, Tran NL, McDonough WS, Berens ME. EphB2/R-Ras signaling regulates glioma cell adhesion, growth, and invasion. Am J Pathol 2005; 167: 565-76.
77. Noren NK, Pasquale EB. Eph receptor-ephrin bidirectional signals that target Ras and Rho proteins. Cell Signal 2004; 16: 655-66.
78. Zou JX, Wang B, Kalo MS, Zisch AH, Pasquale EB, Ruoslahti E. An Eph receptor regulates integrin activity through R-Ras. Proc Natl Acad Sci USA 1999; 96: 13813-8.
79. Miao H, Wei BR, Peehl DM, et al. Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK pathway. Nat Cell Biol 2001; 3: 527-30.
80. Dail M, Richter M, Godement P, Pasquale EB. Eph receptors inactivate R-Ras through different mechanisms to achieve cell repulsion. J Cell Sci 2006; 119: 1244-54.
81. Xiao Z, Carrasco R, Kinneer K, et al. EphB4 promotes or suppresses Ras/MEK/ERK pathway in a context-dependent manner: Implications for EphB4 as a cancer target. Cancer Biol Ther 2012; 13: 630-7.
82. Filchtinski D, Sharabi O, Ruppel A, Vetter IR, Herrmann C, Shifman JM. What Makes Ras an Efficient Molecular Switch: A Computational, Biophysical, and Structural Study of Ras-GDP Interactions with Mutants of Raf. J Mol Biol 2010; 399: 422-35.
83. Shima F, Ijiri Y, Muraoka S, et al. Structural basis for conformational dynamics of GTP-bound Ras protein. J Biol Chem 2010; 285: 22696-705.
84. Araki M, Shima F, Yoshikawa Y, et al. Solution structure of the state 1 conformer of GTP-bound H-Ras protein and distinct dynamic properties between the state 1 and state 2 conformers. J Biol Chem 2011; 286: 39644-53.
85. Kobayashi C, Saito S. Relation between the Conformational Heterogeneity and Reaction Cycle of Ras Molecular Simulation of Ras. Biophysical J 2010; 99: 3726-34.
86. Buhrman G, Holzapfel G, Fetics S, Mattos C. Allosteric modulation of Ras positions Q61 for a direct role in catalysis. Proc Natl Acad Sci USA 2010; 107: 4931-6.
87. Holzapfel G, Buhrman G, Mattos C. Shift in the Equilibrium between On and Off States of the Allosteric Switch in Ras-GppNHp Affected by Small Molecules and Bulk Solvent Composition. Biochemistry 2012; 51: 6114-26.
88. Buhrman G, O'Connor C, Zerbe B, et al. Analysis of binding site hot spots on the surface of Ras GTPase. J Mol Biol 2011; 413: 773-89.
89. Baines AT, Xu D, Der CJ. Inhibition of Ras for cancer treatment: the search continues. Future Med Chem 2011; 3: 1787-808.
90. Gareiss PC, Schneekloth AR, Salcius MJ, Seo SY, Crews CM. Identification and characterization of a peptidic ligand for Ras. Chembiochem 2010; 11: 517-22.
91. Matsunaga-Udagawa R, Fujita Y, Yoshiki S, et al. The scaffold protein Shoc2/SUR-8 accelerates the interaction of Ras and Raf. J Biol Chem 2010; 285: 7818-26.
92. Shu FJ, Ramineni S, Hepler JR. RGS14 is a multifunctional scaffold that integrates G protein and Ras/Raf MAPkinase signalling pathways. Cell Signal 2010; 22: 366-76.
93. Wong KA, Russo A, Wang X, Chen YJ, Lavie A, O'Bryan JP. A new dimension to Ras function: a novel role for nucleotide-free Ras in Class II phosphatidylinositol 3-kinase beta (PI3KC2beta) regulation. PLoS One 2012; 7: e45360.
94. Peracchi A, Mozzarelli A. Exploring and exploiting allostery: Models, evolution, and drug targeting. Biochim Biophys Acta 2010: PMID: 21035570.
95. Kenakin TP. Ligand detection in the allosteric world. J Biomol Screen 2010; 15: 119-30.
96. Schwartz TW, Holst B. Allosteric enhancers, allosteric agonists and ago-allosteric modulators: where do they bind and how do they act? Trends Pharmacol Sci 2007; 28: 366-73.
97. Drag M, Salvesen GS. Emerging principles in protease-based drug discovery. Nat Rev Drug Discov 2010; 9: 690-701.
98. Kenakin T, Miller LJ. Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev 2010; 62: 265-304.
99. Fanali G, Rampoldi V, di Masi A, et al. Binding of anti-Parkinson's disease drugs to human serum albumin is allosterically modulated. IUBMB Life 2010; 62: 371-6.
100. Lawrence SH, Ramirez UD, Selwood T, Stith L, Jaffe EK. Allosteric inhibition of human porphobilinogen synthase. J Biol Chem 2009; 284: 35807-17.
101. Ivetac A, McCammon JA. Mapping the druggable allosteric space of g-protein coupled receptors: a fragment-based molecular dynamics approach. Chem Biol Drug Des 2010; 76: 201-17.
102. Rosenkilde MM, Benned-Jensen T, Frimurer TM, Schwartz TW. The minor binding pocket: a major player in 7TM receptor activation. Trends Pharmacol Sci 2010.
103. Kar G, Keskin O, Gursoy A, Nussinov R. Allostery and population shift in drug discovery. Curr Opin Pharmacol 2010.
104. Cui Q, Karplus M. Allostery and cooperativity revisited. Protein Sci 2008; 17: 1295-307.
105. Tsai CJ, del Sol A, Nussinov R. Allostery: absence of a change in shape does not imply that allostery is not at play. J Mol Biol 2008; 378: 1-11.
106. Gunasekaran K, Ma B, Nussinov R. Is allostery an intrinsic property of all dynamic proteins? Proteins 2004; 57: 433-43.
107. Nussinov R, Tsai CJ. The Different Ways through Which Specificity Works in Orthosteric and Allosteric Drugs. Curr Pharm Des 2012; 18: 1311-1316.
108. Parcej D, Tampe R. ABC proteins in antigen translocation and viral inhibition. Nat Chem Biol 2010; 6: 572-80.
109. Panjkovich A, Daura X. Assessing the structural conservation of protein pockets to study functional and allosteric sites: implications for drug discovery. BMC Struct Biol 2010; 10: 9.
110. Block P, Weskamp N, Wolf A, Klebe G. Strategies to search and design stabilizers of protein-protein interactions: a feasibility study. Proteins 2007; 68: 170-86.
111. Betzi S, Restouin A, Opi S, et al. Protein protein interaction inhibition (2P2I) combining high throughput and virtual screening: Application to the HIV-1 Nef protein. Proc Natl Acad Sci USA 2007; 104: 19256-61.
112. del Sol A, O'Meara P. Small-world network approach to identify key residues in protein-protein interaction. Proteins 2005; 58: 672-82.
113. Brinda KV, Vishveshwara S. Oligomeric protein structure networks: insights into protein-protein interactions. BMC Bioinformatics 2005; 6: 296.
114. Chennubhotla C, Bahar I. Markov propagation of allosteric effects in biomolecular systems: application to GroEL-GroES. Mol Syst Biol 2006; 2: 36.
115. Zheng W, Brooks BR, Thirumalai D. Allosteric transitions in biological nanomachines are described by robust normal modes of elastic networks. Curr Protein Pept Sci 2009; 10: 128-32.
116. Nussinov R, Tsai CJ, Ma B. The (still) underappreciated role of allostery in the cellular network. Annual Rev Biophys 2013; 42, in press.
117. Kraich M, Klein M, Patino E, et al. A modular interface of IL-4 allows for scalable affinity without affecting specificity for the IL-4 receptor. BMC Biol 2006; 4: 13.
118. Chrencik JE, Brooun A, Recht MI, et al. Structure and thermodynamic characterization of the EphB4/Ephrin-B2 antagonist peptide complex reveals the determinants for receptor specificity. Structure 2006; 14: 321-30.